Literature DB >> 1450408

Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells.

B Gansbacher1, K Zier, K Cronin, P A Hantzopoulos, B Bouchard, A Houghton, E Gilboa, D Golde.   

Abstract

Cytokines are important modulators of host antitumor responses. Two of these cytokines, interleukin-2 (IL-2) and interferon gamma (IFN-gamma), are produced after antigen-induced activation of helper lymphocytes. The cytokines are released into the immediate vicinity where they either interact with the appropriate receptors on effector cell populations or are rapidly degraded. To mimic this physiologic release of cytokines at the effector-target site, we used retroviral vectors to transduce melanoma cells with the IL-2 or IFN-gamma cDNA. Five melanoma cell lines were transduced with IL-2- or IFN-gamma-containing vectors and secreted IL-2 at 1 to 40 U/mL/10(6) cells/24 h or IFN-gamma 1 to 8 U/mL/10(6) cells/24 h, respectively. After gamma irradiation, these cells continued to secrete cytokines for about 3 to 4 weeks. Secretion of IFN-gamma induced upregulation of major histocompatibility complex class I molecules in a subset of melanoma cell lines. IL-2 production by human melanoma xenografts induced tumor rejection in BALB/c nu/nu mice, showing the in vivo effect of this cytokine. This study shows that (1) human melanoma cells can be stably transduced with cytokine-containing retroviral vectors; (2) cytokines are secreted constitutively by the transduced tumor cells and have the expected biologic effects in vitro and in vivo; and (3) after gamma irradiation, cytokines continue to be secreted for several weeks. These data suggest that irradiated cytokine-secreting allogenic or autologous tumor cells can be used in vaccination protocols for cancer patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1450408

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

Review 1.  Relevance of the T cell receptor for immunotherapy of cancer.

Authors:  E Weidmann; M Trucco; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

2.  Preservation of the bystander cytocidal effect of irradiated herpes simplex virus thymidine kinase (HSV-tk) modified tumor cells.

Authors:  F D Vrionis; J K Wu; P Qi; W G Cano; V Cherington
Journal:  J Neurooncol       Date:  1996-12       Impact factor: 4.130

Review 3.  Gene therapy of cancer.

Authors:  A Bank
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

4.  Immune reactions induced by interleukin-2 transfected colorectal cancer cells in vitro: predominant induction of lymphokine-activated killer cells.

Authors:  M Lindauer; H K Schackert; J Gebert; W Rudy; A Habicht; M Siebels; S C Meuer; U Moebius
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

Review 5.  Cytokine-mediated gene therapy for cancer.

Authors:  A R Miller; W H McBride; K Hunt; J S Economou
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

6.  Human lung tumor cell secretion of interleukin-2 for protection against tumor engraftment.

Authors:  T Alosco; B Gansbacher; R Bankert; H Takita; N Petrelli
Journal:  Ann Surg Oncol       Date:  1994-05       Impact factor: 5.344

Review 7.  Breast cancer gene therapy: transgenic immunotherapy.

Authors:  N Su; J O Ojeifo; A MacPherson; J A Zwiebel
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment.

Authors:  J Bubeník; J Símová; D Bubeníková; J Zeuthen; M Indrová
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 9.  Viral vectors for gene transfer: a review of their use in the treatment of human diseases.

Authors:  W Walther; U Stein
Journal:  Drugs       Date:  2000-08       Impact factor: 11.431

10.  Cancer vaccine development: designing tumor cells for greater immunogenicity.

Authors:  Erica N Bozeman; Rangaiah Shashidharamurthy; Simon A Paulos; Ravi Palaniappan; Martin D'Souza; Periasamy Selvaraj
Journal:  Front Biosci (Landmark Ed)       Date:  2010-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.